From cb8d204e5fcd8cc9fb0c1d0888a763ce85a37275 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 16 Mar 2026 13:59:30 +0000 Subject: [PATCH] extract: 2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes Pentagon-Agent: Ganymede --- ... net cost impact inflationary through 2035.md | 6 ++++++ ...ney-cardiovascular-and-metabolic-endpoints.md | 6 ++++++ ...-creating-largest-per-patient-cost-savings.md | 6 ++++++ ...ejm-flow-trial-semaglutide-kidney-outcomes.md | 16 +++++++++++++++- 4 files changed, 33 insertions(+), 1 deletion(-) diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index dc7e4b78..2bc9d0db 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -41,6 +41,12 @@ MA plans' near-universal prior authorization creates administrative friction tha MASH/NASH is projected to become the leading cause of liver transplantation. GLP-1s now demonstrate efficacy across three major organ systems (cardiovascular, renal, hepatic), which strengthens the multi-indication economic case for chronic use. The 62.9% MASH resolution rate suggests GLP-1s could prevent progression to late-stage liver disease and transplantation, though the Value in Health Medicare study showed only $28M MASH savings—surprisingly small given clinical magnitude, likely because MASH progression to transplant takes decades and falls outside typical budget scoring windows. + +### Additional Evidence (extend) +*Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-16* + +FLOW trial provides the strongest per-patient economic case for GLP-1s: slowing eGFR decline by 1.16 mL/min/1.73m2 annually delays or prevents dialysis ($90K+/year per patient). CKD progression prevention represents the largest downstream savings opportunity because the cost differential between chronic medication and dialysis is an order of magnitude larger than for other GLP-1 indications. + --- Relevant Notes: diff --git a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md index 22e50070..73da5d0d 100644 --- a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md +++ b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md @@ -42,6 +42,12 @@ SELECT trial exploratory analysis (N=17,604, median 41.8 months) shows semagluti Phase 3 trial shows semaglutide 2.4mg achieves 62.9% resolution of steatohepatitis without worsening fibrosis vs 34.3% placebo. Meta-analysis confirms GLP-1 RAs significantly increase histologic resolution of MASH, decrease liver fat deposition, improve hepatocellular ballooning, and reduce lobular inflammation. Some hepatoprotective benefits appear at least partly independent of weight loss, suggesting direct liver effects beyond metabolic improvement. This adds hepatic protection as a third major organ system (alongside cardiovascular and renal) where GLP-1s demonstrate protective effects. + +### Additional Evidence (confirm) +*Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-16* + +FLOW trial demonstrated simultaneous kidney protection (24% reduction in major kidney events), cardiovascular protection (29% reduction in CV death, 18% reduction in major CV events), and metabolic benefits in a single trial population. Separate analysis showed additive benefits when combined with SGLT2 inhibitors, confirming multi-pathway organ protection. + --- Relevant Notes: diff --git a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md index 5299ec09..f1536940 100644 --- a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md +++ b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md @@ -28,6 +28,12 @@ This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist, - FDA indication expansion to T2D patients with CKD (2024) - Dialysis cost benchmark: $90K+/year per patient + +### Additional Evidence (confirm) +*Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-16* + +FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major kidney disease events (HR 0.76, P=0.0003), 29% reduction in cardiovascular death (HR 0.71), and slowed eGFR decline by 1.16 mL/min/1.73m2 annually. Trial stopped early for efficacy. FDA subsequently expanded Ozempic indications to include CKD in T2D patients. This is the first dedicated kidney outcomes trial for any GLP-1 agonist. + --- Relevant Notes: diff --git a/inbox/archive/2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes.md b/inbox/archive/2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes.md index 4ba699c0..016bc2da 100644 --- a/inbox/archive/2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes.md +++ b/inbox/archive/2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes.md @@ -7,9 +7,13 @@ date: 2024-05-29 domain: health secondary_domains: [] format: paper -status: unprocessed +status: enrichment priority: high tags: [glp-1, semaglutide, CKD, kidney-disease, FLOW-trial, organ-protection] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -38,3 +42,13 @@ Additive benefits when used with SGLT2 inhibitors (separate analysis in Nature M PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] WHY ARCHIVED: Kidney protection is where GLP-1 downstream savings are largest per-patient — dialysis prevention is the economic mechanism most favorable to the VBC cost-saving thesis EXTRACTION HINT: Focus on the economic implications of slowed kidney decline for capitated payers, not just the clinical endpoint + + +## Key Facts +- FLOW trial enrolled 3,533 patients with type 2 diabetes and chronic kidney disease +- Median follow-up was 3.4 years before early stopping +- Primary composite endpoint showed HR 0.76 (P=0.0003) +- Cardiovascular death HR was 0.71 (95% CI 0.56-0.89) +- Annual eGFR slope difference was 1.16 mL/min/1.73m2 (P<0.001) +- Dialysis costs approximately $90,000+ per year per patient +- FDA expanded Ozempic indications to include CKD in T2D patients following FLOW results